logo

Steadymed Ltd. (STDY)



Trade STDY now with
  Date
  Headline
12/8/2017 6:56:50 AM SteadyMed Announces FDA Agreed Pathway To Trevyent NDA Resubmission
11/14/2017 9:57:39 AM SteadyMed Gets Favorable Ruling From U.S. Court Of Appeals For Federal Circuit
11/13/2017 8:37:38 AM SteadyMed Q3 Net Income $9.4 Mln Or $0.35/Shr Vs Net Loss $10.0 Mln Or $0.57/Shr Last Year
10/12/2017 8:35:56 AM SteadyMed Receives Notice Of Allowance For European Patent Relating To Enhanced Reduction Of Infusion-Site Pain
8/31/2017 6:46:28 AM SteadyMed Reports Receipt Of A Refusal To File Letter From FDA Relating To NDA For Trevyent
8/11/2017 8:34:35 AM SteadyMed Q2 Net Loss $8.1 Mln Or $0.33/Shr Vs Loss Of $7.2 Mln Or $0.53/Shr Last Year
7/31/2017 8:32:49 AM SteadyMed Appoints Jeff Myers As VP, Medical Affairs
7/3/2017 8:02:53 AM Cardiome's Partner SteadyMed Submits U.S. NDA For TREVYENT For Treatment Of Pulmonary Arterial Hypertension
5/26/2017 8:44:32 AM SteadyMed Raises Additional Capital From A Key Institutional Shareholder
5/2/2017 8:35:46 AM SteadyMed Gets USPTO Notice Of Allowance For Patent Related To Key PatchPump Technology
4/21/2017 8:11:21 AM SteadyMed Raises $30 Mln In Private Placement; Prepares To File NDA For Trevyent In Q2
9/1/2016 8:30:34 AM SteadyMed Completes Pre-NDA Submission Manufacturing Activities
5/11/2016 8:35:15 AM SteadyMed Q1 Loss Per Share $0.46 Vs Loss $4.35 Last Year
4/11/2016 7:12:19 AM SteadyMed Unveils Initiation Of Inter Partes Review Proceedings By USPTO Against A United Therapeutics Patent